Top

Published in:

01-12-2012 | Review Article

Pharmacodynamic Models for Discrete Data

Authors: Ines Paule, Pascal Girard, Gilles Freyer, Michel Tod

Published in: Clinical Pharmacokinetics | Issue 12/2012

Abstract

Clinical outcomes are often described as events: death, stroke, epileptic seizure, multiple sclerosis lesions, recurrence of cancer, disease progression, pain, infection and bacterial/viral eradication, severe toxic adverse effect, resistance to treatment, etc. They may be quantified as time-to-event, counts of events per time interval (rates), their severity grade, or a combination of these. Such data are discrete and require specific modelling structures and methods. This article references the most common modelling approaches for categorical, count and time-to-event data, and reviews examples of such models applied in the analysis of pharmacodynamic data. Modelling is useful for identification of influential factors related to the clinical outcome, characterization and quantification of their impact, for making better informed predictions and clinical decisions, assessments of efficacy of therapeutic interventions, optimizing the individual treatments and drug development studies.

Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics ans pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979;25(3):358–71.CrossRefPubMed

Sheiner LB. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther. 1994;56:309–22.CrossRefPubMed

Sheiner LB, Beal SL, Dunne A. Analysis of non-randomly censored ordered categorical longitudinal data from analgesic trials. J Am Stat Assoc. 1997;92:1235–44.CrossRef

Raman R, Hedeker D. A mixed-effects regression model for three-level ordinal response data. Stat Med. 2005;24:3331–45.CrossRefPubMed

Liu I, Agresti A. The analysis of ordered categorical data: an overview and a survey of recent developments. Sociedad de Estadistica e Investigacion Operativa Test. 2005; 14(1):1–73. http://www.stat.ufl.edu/~aa/articles/liu_agresti_2005.pdf. Accessed 2 Oct 2012.

McCullagh P. Regression models for ordinal data (with discussion). J R Stat Soc B. 1980;42:109–42.

Zingmark PH. Models for ordered categorical pharmacodynamic data [PhD thesis]. Uppsala: Acta Universitatis Upsaliensis; 2005.

Peterson B, Harrell FE Jr. Partial proportional odds models for ordinal response variables. Appl Stat. 1990;39(2):205–17.CrossRef

Agresti A. Modelling ordered categorical data: recent advances and future challenges. Stat Med. 1999;18:2191–207.CrossRefPubMed

10.

Lindsey JK, Jones B, Ebbutt AF. Simple models for repeated ordinal responses with an application to a seasonal rhinitis clinical trials. Stat Med. 1997;16:2873–82.CrossRefPubMed

11.

Vermunt JK, Hagenaars JA. Ordinal longitudinal data analysis: methods in human growth research. In: Hauspie RC, Cameron N, Molinari L, editors. Cambridge: Cambridge University Press; 2004. p. 374–93.

12.

Hartzel J, Agresti A, Caffo B. Multinomial logit random effects models. Stat Model. 2001;1:81–102.CrossRef

13.

Anderson JA, Philips PR. Regression, discrimination and measurement models for ordered categorical variables. Appl Stat. 1981;30:22–31.CrossRef

14.

Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2008;35(2):139–57.CrossRefPubMed

15.

Girard P, Blaschke TF, Kastrissios H, Sheiner LB. A Markov mixed effect regression model for drug compliance. Stat Med. 1998;17(20):2313–33.CrossRefPubMed

16.

Ito K, Hutmacher M, Liu J, Qiu R, Frame B, Miller R. Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder. Clin Pharmacol Ther. 2008;84(1):127–35.CrossRefPubMed

17.

Henin E, You B, VanCutsem E, et al. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther. 2009;85:418–25.CrossRefPubMed

18.

Troconiz IF, Plan EL, Miller R, Karlsson MO. Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn. 2009;36(5):461–77.CrossRefPubMed

19.

Lee ET, Wang JW. Statistical methods for survival data analysis. 3rd ed. Hoboken: John Wiley & Sons, Inc.; 2003.CrossRef

20.

Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn. 2003;30(1):83–103.CrossRefPubMed

21.

Meira-Machado L, de Uña-Alvarez J, Cadarso-Suárez C, et al. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009;18(2):195–222.CrossRefPubMed

22.

Anisimov VV, Maas HJ, Danhof M, Della Pasqua O. Analysis of responses in migraine modelling using hidden Markov models. Stat Med. 2007;26(22):4163–78.CrossRefPubMed

23.

Aarons L, Graham G. Methodological approaches to the population analysis of toxicity data. Toxicol Lett. 2001;120(1–3):405–10.CrossRefPubMed

24.

Barras MA, Duffull SB, Atherton JJ, Green B. Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. Br J Clin Pharmacol. 2009;68(5):700–11.CrossRefPubMedPubMedCentral

25.

Claret L, Cox EH, McFadyen L, et al. Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra). Pharm Res. 2006;23(8):1756–64.CrossRefPubMed

26.

Dartois C, Freyer G, Michallet M, et al. Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. Clin Pharmacokinet. 2007;46(5):417–32.CrossRefPubMedPubMedCentral

27.

Diack C, Bois FY. Pharmacokinetic-pharmacodynamic models for categorical toxicity data. Regul Toxicol Pharmacol. 2005;41(1):55–65.CrossRefPubMed

28.

Garrido MJ, Habre W, Rombout F, et al. Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res. 2006;23(9):2014–23.CrossRefPubMed

29.

Geldof M, Freijer J, van Beijsterveldt L, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. Eur J Pharm Sci. 2007;32(3):200–8.CrossRefPubMed

30.

Gieschke R, Burger HU, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol. 2003;55(3):252–63.CrossRefPubMedPubMedCentral

31.

Graham G, Gupta S, Aarons L. Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data. J Pharmacokinet Pharmacodyn. 2002;29(1):67–88.CrossRefPubMed

32.

Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterization of therapeutic index: Application of mixed-effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships. Clin Pharmacol Ther. 1999;65(6):672–84.CrossRefPubMed

33.

Carlsson KC, Savić RM, Hooker AC, Karlsson MO. Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making. AAPS J. 2009;11(1):148–54.CrossRefPubMedPubMedCentral

34.

Knibbe CA, Zuideveld KP, DeJongh J, et al. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther. 2002;72(6):670–84.CrossRefPubMed

35.

Kowalski KG, McFadyen L, Hutmacher MM, et al. A two-part mixture model for longitudinal adverse event severity data. J Pharmacokinet Pharmacodyn. 2003;30(5):315–36.CrossRefPubMed

36.

Kowalski KG, Olson S, Remmers AE, Hutmacher MM. Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. Clin Pharmacol Ther. 2008;83(6):857–66.CrossRefPubMed

37.

Lunn DJ, Wakefield J, Racine-Poon A. Cumulative logit models for ordinal data: a case study involving allergic rhinitis severity scores. Stat Med. 2001;20(15):2261–85.CrossRefPubMed

38.

Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther. 1996;60(6):619–35.CrossRefPubMed

39.

Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther. 2002;71(5):334–48.CrossRefPubMed

40.

Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther. 2002;72(3):265–75.CrossRefPubMed

41.

Zingmark PH, Edenius C, Karlsson MO. Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. Br J Clin Pharmacol. 2004;58(4):378–89.CrossRefPubMedPubMedCentral

42.

Zingmark PH, Kågedal M, Karlsson MO. Modelling a spontaneously reported side effect by use of a Markov mixed-effects model. J Pharmacokinet Pharmacodyn. 2005;32(2):261–81.CrossRefPubMed

43.

Brown MS, Barón AE, France EK, Hamman RF. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J AAPOS. 2006;10(2):143–9.CrossRefPubMed

44.

Jönsson S, Kjellsson MC, Karlsson MO. Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED. J Pharmacokinet Pharmacodyn. 2004;31(4):299–320.CrossRefPubMed

45.

Paule I, Girard P, Tod M. Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data. Comput Methods Programs Biomed. 2011;104(3):505–13.CrossRefPubMed

46.

Paule I, Tod M, Henin E, et al. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation. Cancer Chemother Pharmacol. 2012;69(2):447–55.CrossRefPubMed

47.

Miller R, Frame B, Corrigan B, et al. Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin Pharmacol Ther. 2003;73(6):491–505.CrossRefPubMed

48.

Frame B, Miller R, Lalonde RL. Evaluation of mixture modeling with count data using NONMEM. J Pharmacokinet Pharmacodyn. 2003;30(3):167–83.CrossRefPubMed

49.

Snoeck E, Stockis A. Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res. 2007;73(3):284–91.CrossRefPubMed

50.

Ogungbenro K, Aarons L. Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements. J Biopharm Stat. 2010;20(5):1026–42.CrossRefPubMed

51.

Collin F, Chêne G, Retout S, et al. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. Ther Drug Monit. 2007;29(2):164–70.CrossRefPubMed

52.

Cox EH, Veyrat-Follet C, Beal SL, et al. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm. 1999;27(6):625–44.CrossRefPubMed

53.

Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073–81.CrossRefPubMedPubMedCentral

54.

Forrest A, Chodosh S, Amantea MA, et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1997;40 Suppl A:45–57.CrossRefPubMed

55.

Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66(2):357–71.CrossRefPubMed

56.

Hu C, Szapary PO, Yeilding N, Zhou H. Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn. 2011;38(2):237–60.CrossRefPubMed

57.

Joerger M, Huitema AD, Krähenbühl S, Schellens JH, Cerny T, Reni M, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102(4):673–7.CrossRefPubMedPubMedCentral

58.

Tod M, Farcy-Afif M, Stocco J, et al. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet. 2005;44(4):417–28.CrossRefPubMed

59.

Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther. 2000;68(6):677–87.CrossRefPubMed

60.

Weber W, Harnisch L, Jessel A, et al. Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery. Clin Pharmacol Ther. 2002;71(6):457–67.CrossRefPubMed

61.

You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, et al. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer. 2008;62(2):261–72.CrossRefPubMed

62.

Karlsson MO, Schoemaker RC, Kemp B, et al. A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Clin Pharmacol Ther. 2000;68(2):175–88.CrossRefPubMed

63.

Keizer RJ, Gupta A, Mac Gillavry MR, et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn. 2010;37:347–63.CrossRefPubMedPubMedCentral

64.

Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO. Modeling sleep data for a new drug in development using markov mixed-effects models. Pharm Res. 2011;28(10):2610–27.CrossRefPubMed

65.

Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2009;86(4):387–95.CrossRefPubMed

66.

Maas HJ, Danhof M, Della Pasqua O. A model-based approach to treatment comparison in acute migraine. Br J Clin Pharmacol. 2006;62(5):591–600.CrossRefPubMedPubMedCentral

Title: Pharmacodynamic Models for Discrete Data
Authors: Ines Paule
Pascal Girard
Gilles Freyer
Michel Tod
Publication date: 01-12-2012
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 12/2012
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-012-0014-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacodynamic Models for Discrete Data

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2012

Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy

Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women

Population Pharmacokinetic Analysis during the First 2 Years of Life

Erratum to: Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

Acknowledgement